

Clinical Policy: Clobazam (Onfi, Sympazan)

Reference Number: CP.PMN.54

Effective Date: 11.01.12

Last Review Date: 11.24

Line of Business: Commercial, HIM, Medicaid

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Clobazam (Onfi[®], Sympazan[®]) is a benzodiazepine.

FDA Approved Indication(s)

Onfi and Sympazan are indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation[®] that Onfi, Sympazan, and generic clobazam are **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Lennox-Gastaut Syndrome (must meet all):

1. Diagnosis of LGS;
2. Prescribed by or in consultation with a neurologist;
3. Age \geq 2 years;
4. Member meets one of the following (a or b):
 - a. Request is for the treatment of a member in a State with limitations on step therapy in certain settings (*see Appendix D*);
 - b. Failure of 2 preferred agents for LGS (e.g., clonazepam, valproic acid (divalproex), lamotrigine, topiramate, felbamate), unless clinically significant adverse effects are experienced or all are contraindicated;
5. Member meets one of the following (a or b):
 - a. Request is for the treatment of a member in a State with limitations on step therapy in certain settings (*see Appendix D*);
 - b. For Onfi and Sympazan requests, member must use generic clobazam tablets or oral suspension, unless clinically significant adverse effects are experienced or both are contraindicated;
6. Dose does not exceed any of the following (a and b):
 - a. 40 mg per day;
 - b. 2 tablets per day, 16 mL per day, or 2 films per day.

Approval duration:

Medicaid/HIM – 12 months

Commercial – 12 months or duration of request, whichever is less

B. Intractable/Refractory Epilepsy (off-label) (must meet all):

1. Diagnosis of intractable/refractory epilepsy;
2. Prescribed by or in consultation with a neurologist;
3. Age \geq 2 years;
4. Member meets one of the following (a or b):
 - a. Request is for the treatment of a member in a State with limitations on step therapy in certain settings (*see Appendix D*);
 - b. Failure of \geq 4 anti-seizure drugs (*see Appendix B*), unless clinically significant adverse effects are experienced or all are contraindicated;
5. Member meets one of the following (a or b):
 - a. Request is for the treatment of a member in a State with limitations on step therapy in certain settings (*see Appendix D*);
 - b. For Onfi and Sympazan requests, member must use generic clobazam tablets or oral suspension, unless clinically significant adverse effects are experienced or both are contraindicated;
6. Dose does not exceed any of the following (a and b):
 - a. 40 mg per day;
 - b. 2 tablets per day, 16 mL per day, or 2 films per day.

Approval duration:

Medicaid/HIM – 12 months

Commercial – 12 months or duration of request, whichever is less

C. Dravet Syndrome (off-label) (must meet all):

1. Diagnosis of Dravet syndrome;
2. Prescribed by or in consultation with a neurologist;
3. Age \geq 2 years;
4. For Onfi and Sympazan requests, member must use generic clobazam tablets or oral suspension, unless clinically significant adverse effects are experienced or both are contraindicated;
5. Dose does not exceed 2 mg/kg per day.

Approval duration:

Medicaid/HIM – 12 months

Commercial – 12 months or duration of request, whichever is less

D. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace, and CP.PMN.255 for Medicaid; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business:

CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace, and CP.PMN.16 for Medicaid; or

2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

II. Continued Therapy

A. All Indications in Section I (must meet all):

1. Currently receiving medication via Centene benefit, or documentation supports that member is currently receiving Onfi or Sympazan for a covered indication and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. If request is for a dose increase, new dose does not exceed any of the following (a or b):
 - a. LGS or intractable/refractory epilepsy – any of the following (i or ii):
 - i. 40 mg per day;
 - ii. 2 tablets per day, 16 mL per day, or 2 films per day;
 - b. Dravet syndrome: 2 mg/kg per day.

Approval duration:

Medicaid/HIM – 12 months

Commercial – 12 months or duration of request, whichever is less

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace, and CP.PMN.255 for Medicaid; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies –

CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace and CP.PMN.53 for Medicaid, or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

FDA: Food and Drug Administration

LGS: Lennox-Gastaut syndrome

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

| Drug Name | Dosing Regimen | Dose Limit/ Maximum Dose |
|---|----------------------------------|----------------------------------|
| Anticonvulsants-benzodiazepines | | |
| clonazepam (Klonopin [®]) | See full prescribing information | See full prescribing information |
| diazepam rectal gel (Diastat [®]) | | |
| Carbamates | | |
| felbamate (Felbatol [®]) | See full prescribing information | See full prescribing information |
| GABA modulators | | |
| vigabatrin (Sabril [®]) | See full prescribing information | See full prescribing information |
| tiagabine (Gabitril [®]) | | |
| Hydantoins | | |
| phenytoin (Dilantin [®]) | See full prescribing information | See full prescribing information |
| Succinimides | | |
| ethosuximide (Zarontin [®]) | See full prescribing information | See full prescribing information |
| methsuximide (Celontin [®]) | | |
| Valproic acid | | |
| divalproex sodium (Depakote [®]) | See full prescribing information | See full prescribing information |
| valproic acid (Depakene [®]) | | |
| AMPA glutamate receptor antagonists | | |
| Fycompa [®] (perampanel) | See full prescribing information | See full prescribing information |
| Anticonvulsants-miscellaneous | | |
| Briviact [®] [brivaracetam], carbamazepine [Tegretol [®] , Tegretol XL [®]], Aptiom [®] [eslicarbazepine], gabapentin [Neurontin [®]], lacosamide [Vimpat [®]], lamotrigine [Lamictal [®]], levetiracetam [Keppra [®] , Spritam [®]], oxcarbazepine [Oxtellar XR [®] , | See full prescribing information | See full prescribing information |

| Drug Name | Dosing Regimen | Dose Limit/ Maximum Dose |
|--|----------------|-----------------------------|
| Trileptal [®]], pregabalin [Lyrica [®]], primidone [Mysoline [®]], rufinamide [Banzel [®]], topiramate [Topamax [®] , Qudexy XR [®] , Trokendi XR [®]], zonisamide [Zonegran [®]]) | | |

Therapeutic alternatives are listed as Brand name[®] (generic) when the drug is available by brand name only and generic (Brand name[®]) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): history of hypersensitivity to the drug or its ingredients
- Boxed warning(s): risks from concomitant use with opioids; abuse, misuse, and addiction; dependence and withdrawal reactions

Appendix D: States with Limitations against Redirections in Certain Settings

| State | Step Therapy Prohibited? | Notes |
|-------|--------------------------|--|
| NV | No | <p><i>*Applies to Medicaid requests only*</i></p> <ul style="list-style-type: none"> • LGS: Failure of ONE of the following, unless clinically significant adverse effects are experienced or all are contraindicated: generic clobazam tablets, generic clobazam oral suspension, alternative drug for LGS (e.g., clonazepam, valproic acid (divalproex), lamotrigine, topiramate, felbamate) • Intractable/refractory epilepsy: Failure of ONE of the following, unless clinically significant adverse effects are experienced or all are contraindicated: generic clobazam tablets, generic clobazam oral suspension, alternative anti-seizure drug (<i>see Appendix B</i>) |

V. Dosage and Administration

| Indication | Dosing Regimen | Maximum Dose |
|------------|--|--|
| LGS | <p>Patients ≤ 30 kg body weight: initiate at 5 mg PO daily and titrate as tolerated up to 20 mg daily</p> <p>Patients > 30 kg body weight: initiate at 10 mg PO daily and titrate as tolerated up to 40 mg daily</p> <p>A daily dose greater than 5 mg should be administered in divided doses twice daily; a 5 mg daily dose can be administered as a single dose.</p> | <p>≤ 30 kg body weight: 20 mg/day</p> <p>> 30 kg body weight: 40 mg/day</p> |

| Indication | Dosing Regimen | Maximum Dose |
|---|--|--------------|
| Intractable/refractory epilepsy (off-label) | See LGS | See LGS |
| Dravet syndrome (off-label) | Initial: 0.2-0.3 mg/kg/day PO Maximum: 0.5-2 mg/kg/day PO | See regimen |

VI. Product Availability

| Drug Name | Availability |
|---------------------|--|
| Clobazam (Onfi) | Tablet with a functional score: 10 mg, 20 mg Oral suspension: 2.5 mg/mL in 120 mL bottles |
| Clobazam (Sympazan) | Oral film: 5 mg, 10 mg, 20 mg |

VII. References

1. Onfi Prescribing Information. Deerfield, IL: Lundbeck; March 2024. Available at: <https://www.onfihcp.com/>. Accessed July 15, 2024.
2. Sympazan Prescribing Information. Warren, NJ: Aquestive Therapeutics; March 2024. Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2023/210833s0041bl.pdf. Accessed July 15, 2024.
3. Hancock EC, Cross JH. Treatment of Lennox-Gastaut syndrome. *Cochrane Database Syst Rev*. 2013 Feb 28;(2).
4. Arzimanoglou A, French J, Blume WT, et al. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. *Lancet Neurol*. 2009 Jan;8(1):82-93.
5. Verrotti A, Striano P, Iapadre G, et al. The pharmacological management of Lennox-Gastaut syndrome and critical literature review. *Seizure: European Journal of Epilepsy*. 2018;63:17-25.
6. Mills JK, Lewis TG, Mughal K, et al. Retention rate of clobazam, topiramate and lamotrigine in children with intractable epilepsies at 1 year. *Seizure*. 2011 June;20(5): 402-405.
7. Gauthier AC, Mattson RH. Clobazam: a safe, efficacious, and newly rediscovered therapeutic for epilepsy. *CNS Neurosci Ther*. 2015 Jul;21(7):543-8.
8. Montenegro MA, Arif H, Nahm EA, et al. Efficacy of clobazam as add-on therapy for refractory epilepsy: experience at a US epilepsy center. *Clin Neuropharmacol*. 2008 Nov-Dec;31(6):333-8.
9. Cross JH, Auvin S, Falip M, et al. Expert Opinion on the Management of Lennox–Gastaut Syndrome: Treatment Algorithms and Practical Considerations. *Frontiers in Neurology*. 2017;8:505.
10. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2018. Available at: <http://www.clinicalpharmacology-ip.com/>. Accessed August 16, 2023.
11. Wirrell EC, Laux L, Jette N, et al. Optimizing the diagnosis and management of Dravet syndrome: recommendations from a North American consensus panel. *Pediatr Neurol*. 2017; 68: 18-34.
12. Epilepsies: diagnosis and management. National Institute for Health and Care Excellence (NICE) website. <https://www.nice.org.uk/guidance/CG137/chapter/Appendix-E-Pharmacological-treatment>. Updated April 2018. Accessed August 22, 2018.

13. Practice Guideline Update: Efficacy and Tolerability of the New Antiepileptic Drugs II: Treatment-resistant Epilepsy. American Academy of Neurology. Available at: <https://www.aan.com/Guidelines/Home/GetGuidelineContent/922>. Accessed July 25, 2019.
14. Wirrell EC, Hood V, Knupp KG et al. International consensus on diagnosis and management of Dravet syndrome. *Epilepsia*. 2022;63:1761-77. DOI: 10.1111/epi.17274.
15. Montouris G, Aboumatar S, Burdette D, et al. Expert opinion: proposed diagnostic and treatment algorithms for Lennox-Gastaut syndrome in adult patients. *Epilepsy & Behavior*. September 2020;110:107146. <https://doi.org/10.1016/j.yebeh.2020.107146>.

| Reviews, Revisions, and Approvals | Date | P&T Approval Date |
|---|----------|-------------------|
| 4Q 2020 annual review: no significant changes; for HIM line of business removed references to non-formulary policy for Sympazan; references reviewed and updated. | 08.04.20 | 11.20 |
| 4Q 2021 annual review: no significant changes; revised “Medical justification...for clobazam tablets and oral suspension...” to “Member must use clobazam tablets or oral suspension...”; revised HIM.PHAR.21 to HIM.PA.154; references reviewed and updated. | 08.20.21 | 11.21 |
| Revised approval duration for Commercial line of business from length of benefit to 12 months or duration of request, whichever is less | 01.20.22 | 05.22 |
| 4Q 2022 annual review: no significant changes; references reviewed and updated. Template changes applied to other diagnoses/indications and continued therapy section. | 08.25.22 | 11.22 |
| For LGS and intractable/refractory epilepsy, added redirection bypass for members in a State with limitations on step therapy in certain settings along with Appendix D, which includes Nevada with requirements for single drug redirection for Medicaid requests. | 08.31.23 | |
| 4Q 2023 annual review: no significant changes; references reviewed and updated. | 09.06.23 | 11.23 |
| 4Q 2024 annual review: no significant changes; references reviewed and updated. | 07.15.24 | 11.24 |

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health

plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan's affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:

For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2012 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise

published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.